Based in Paris, France, THERAVECTYS is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Their first clinical studies will be in HIV/AIDS, using their lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates. THERAVECTYS is proud to announce the completion of a 7.5 M€ round of financing. Camden Associates advised THERAVECTYS.

Visit website